|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2003-6-25
|
|
pubmed:abstractText |
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1568-70
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12824799-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:12824799-Drug Resistance, Viral,
pubmed-meshheading:12824799-HIV Reverse Transcriptase,
pubmed-meshheading:12824799-HIV-1,
pubmed-meshheading:12824799-Humans,
pubmed-meshheading:12824799-Mutation,
pubmed-meshheading:12824799-Nevirapine,
pubmed-meshheading:12824799-Prospective Studies,
pubmed-meshheading:12824799-Reverse Transcriptase Inhibitors,
pubmed-meshheading:12824799-Stavudine,
pubmed-meshheading:12824799-Treatment Failure
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine.
|
|
pubmed:affiliation |
Servizio di Virologia, IRCCS Policlinico San Matteo, Pavia, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
